"Neoadjuvant therapy” refers to supplemental cancer treatment you receive before your primary treatment. Adjuvant therapies, ...

Patients with previously untreated, high-risk locally advanced cervical cancer experienced improved survival when treated ...

Phase 3 KEYNOTE-630 trial of Keytruda for the adjuvant treatment of patients with high-risk locally advanced cutaneous squamous cell carcinoma (cSCC) following surgery and radiation, based on the ...

Keytruda’s long-term rival, Bristol Myers Squibb’s Opdivo (nivolumab), has received approval for first-line treatment in mGEJ, but this was only for HER2- patients following evidence presented ...

Positive opinion granted for KEYTRUDA plus chemotherapy for the first-line treatment of adult patients with primary advanced or recurrent endometrial carcinoma who are candidates for systemic ...

The combo treatment reduced the risk of death by 21% at the trial's final analysis. Adverse reactions were generally similar to those in other patients receiving Keytruda and chemotherapy ...

Within months, regulators had approved two of the treatments, at first for melanoma. The story — and the transformative impact — of Bristol Myers Squibb’s Opdivo and Merck’s Keytruda ...

Over the past 10 years, PARP inhibitors, immunotherapy and antibody drug conjugates have changed the treatment landscape of gynecologic ... are inflammation in the skin, so rashes, inflammation in the ...

Merck & Co. Inc. said Wednesday the U.S. Food and Drug Administration has approved its blockbuster cancer drug Keytruda as a treatment for malignant plural mesothelioma, a rare cancer associated ...

Positive opinion granted for KEYTRUDA plus chemotherapy for the first-line treatment of adult patients with primary advanced or recurrent endometrial carcinoma who are candidates for systemic therapy, ...